Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
pharmaphorum18d
Sanofi's immunotherapy Libtayo gets FDA approval in first line lung cancer
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
pharmaphorum20d
Sanofi, Regeneron prep filings for Libtayo in cervical cancer
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...
USA Today20d
The USPS, UPS SurePost delivery contract is over. Will this impact how you get packages?
U.S. Postal Service (USPS) workers will no longer deliver UPS SurePost packages after the government agency's contract with the parcel service expired this year. The International Brotherhood of ...
whattowatch20d
Sky TV price, packages, channel guide and everything else you need to know
Plus, some new subscribers might get confused by all the various packages and bundles, especially with Sky often tweaking pricing and adding deals on the fly. To give you a helping hand, we've taken a ...
Seeking Alpha22d
Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...
Pharmabiz22d
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Business Insider22d
Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success
Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...
PMLiVE22d
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...
Benzinga.com23d
Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...
BioSpace23d
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
Regeneron Pharmaceuticals on Monday presented positive Phase III data for its PD-1 inhibitor Libtayo, which yielded significant survival benefits when used as an adjuvant treatment for patients with ...